Relapse-free survival data showed that breast cancer patients with low Nrf2 expression had a lower incidence of relapse compare to those with high Nrf2 expression in the PR+/ER+ (p < 0.05) or TNBC (Triple negative breast cancer) groups. Here, ESR1 is linked to breast cancer.